London
· Delayed Price · Currency is GBP · Price in GBX Oncimmune Holdings Company Description
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally.
The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker.
It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Martin Gouldstone |
Contact Details
Address: 1 Park Row Leeds, LS1 5AB United Kingdom | |
| Website | oncimmune.com |
Stock Details
| Ticker Symbol | ONC |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | September - August |
| Reporting Currency | GBP |
| ISIN Number | GB00BYQ94H38 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Martin Gouldstone | Chief Executive Officer |
| Martin Hudson | Chief Financial Officer |
| Cléa Rosenfeld | Head of Investor Relations |